Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

Prostate

Volumn 42, Issue 1, 2000, Pages 34-44

  Jongsma, Johan ^a,b   Oomen, Monique H A ^a   Noordzij, Marinus A ^a   Romijn, Johannes C ^a   Van Der Kwast, Theodorus H ^a   Schröder, Fritz H ^a   Van Steenbrugge, Gert J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Androgen independence; Neuroendocrine differentiation; Neuropeptides; Proliferation; Prostatic cancer cell lines; Signal transduction

Indexed keywords

2',3' DIDEOXYADENOSINE; ANDROGEN; CALCITONIN; CYCLIC AMP; GASTRIN RELEASING PEPTIDE; NEUROPEPTIDE; PEPTIDE ANTIBODY; PROTEIN BCL 2; QUINOXALINE DERIVATIVE; SEROTONIN; THYMIDINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN INDUCTION;

ANDROGENS; CELL DIVISION; CYCLIC AMP; DIDEOXYADENOSINE; ENZYME INHIBITORS; GASTRIN-RELEASING PEPTIDE; HUMANS; MALE; NEUROPEPTIDES; OXADIAZOLES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOXALINES; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0033986891     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2     Document Type: Article

References (75)

1. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G, Klocker H. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 1997;32:106-114.
2. Chan J, Stampfer M, Giovanucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279: 563-566.
3. Lamm M, Sintich S, Lee C. A proliferative effect of transforming growth factor-β1 on a human prostate cancer cell line, TSU-Pr1. Endocrinology 1998;139:787-790.
4. Peehl D. Cellular biology of prostatic growth factors. Prostate [Suppl] 1996;6:74-8.
5. Zhu X, Liu J-P. Steroid-independent activation of androgen receptor in androgen independent prostate cancer. A possible role for the MAP kinase signal transduction pathway? Mol Cell Endocrinol 1997;134:9-14.
6. Noordzij MA, van Steenbrugge GJ, van der Kwast T, Schröder FH. Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res 1995;22:333-341.
7. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215-1220.
8. Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone-and serotonin-immunoreactive tumor cells in carcinoma of the prostate. Pathol Res Pract 1987; 182:298-307.
9. Seuvwen K, Pouyssegur J. Serotonin as a growth factor. Biochem Pharmacol 1990;39:985-990.
10. Moody TW, Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci 1993;52:1161-1173.
11. Aprikian A, Tremblay L, Han K, Chevalier S. Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase of integrinassociated proteins. Int J Cancer 1997;72:498-504.
12. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-1720.
13. Bold RJ, Lowry PS, Ishizuka J, Battey JF, Townsend CM, Thompson JC. Bombesin stimulates the in vitro growth of a human gastric cancer cell line. J Cell Physiol 1994;161:519-525.
14. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancers. Nature 1985;316:823-826.
15. Speirs V, Bienkowski E, Wong V, Cutz E. Paracrine effects of bombesin/gastrin related peptide and other growth factors on pulmonary neuroendocrine cells in vitro. Anat Rec 1993;236:53-61.
16. Gkonos P, Ashby M, Andrade A. Vasoactive intestinal peptide stimulates prostate specific antigen secretion by LNCaP prostate cancer cells. Regul Pept 1996;65:153-157.
17. Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guyarro LG, Prieto JC. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate. Endocrinology 1996;137:2815-2822.
18. di-Sant'Agnese PA. Calcitonin like immunoreactive and bombesin like immunoreactive endocrine-paracrine cells of the human prostate. Arch Pathol Lab Med 1986;11:412-415.
19. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA. Effects of the calcitrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997;30:183-187.
20. Iwasaki Y, Iwasaki J, Freake HC. Growth inhibition of human breast cancer cells induced by calcitonin. Biochem Biophys Res Commun 1983;110:235-242.
21. Shah GV, Rayford W, Noble NJ, Austenfeld M, Weigel J, Vamos S, Mebust WK. Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates and ctyoplasmic ca2+ transients. Endocrinology 1994;134:596-602.
22. Cramer SD, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. Parathyroid hormone-related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate 1996;29:20-29.
23. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett ATK, Deftos LJ. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675-679.
24. Peehl DM, Edgar MG, Cramer SD, Deftos LJ. Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells. Prostate 1997;31:47-52.
25. Wu G, Iwamura M, Di Sant'agnese P, Deftos L, Cockett A, Gershagen S. Characterization of the cell-specific expression of parathyroid hormone-related protein in normal and neoplastic prostate tissue. Urology 1998;51:110-120.
26. Brevini TAL, Bianchi R, Motta M. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J Clin Endocrinol Metab 1993;77:626-631.
27. Dalsgaard CJ, Hultgardh-Nilsson A, Haegerstrand A, Nilsson J. Neuropeptides as growth factors. Possible roles in human diseases. Regul Pept 1989;25:1-9.
28. Tutton PJ, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells [review]. Anticancer Res 1987;7:1-12.
29. Gkonos PJ, Lokeshwar BL, Balkan W, Roos BA. Neuroendocrine peptides stimulate adenyl cyclase in normal and malignant prostate cells. Regul Pept 1995;59:43-51.
30. Gysbers J, Rathbone M. Neurite outgrowth in PC12 cells is enhanced by guanosine through both cAMP-dependent and -independent mechanisms. Neurosci Lett 1996;220:175-178.
31. Ichikawa T, Suzuki Y, Czaja I, Schommer C, Leßnik A, Schell J, Waiden R. Identification and role of adenylyl cyclase in auxin signaling in higher plants. Nature 1997;390:698-701.
32. Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin and neurotensin. Cancer Res 1991;51:3621-3623.
33. Wasilenko WJ, Cooper J, Palad AJ, Somers KD, Blackmore PF, Rhim JS, Wright GL, Schellhammer PF. Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate 1997;30:167-173.
34. Han K, Viallet J, Chevalier S, Zheng W, Bazinet M, Aprikian AG. Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells. Prostate 1997;31:53-60.
35. Bunn PA, Dienhart DG, Chan D, Puck TT, Tagawa M, Jewett PB, Braunschweiger E. Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways. Proc Natl Acad Sci USA 1990;87:2162-2166.
36. Sinnet-Smith J, Lehmann W, Rozengurt E. Bombesin receptor in membranes from Swiss 3T3 cells. Biochem J 1990;265:485-493.
37. Reid I, Lowe C, Cornish J, Gray D, Skinner S. Adenylate cyclase blockers dissociate PTH-stimulated bone resorption from cAMP production. Am J Physiol 1990;258:708-714.
38. Cellek S, Kasakov L, Moncada S. Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase. Br J Pharmacol 1996;118:137-140.
39. Wessels-Reiker M, Basiboina R, Howlett A, Strong R. Vasoactive intestinal polypeptide-related peptides modulate tyrosine hydroxylase gene expression in PC12 cells through multiple adenylate cyclase-coupled receptors. J Neurochem 1993;60:1018-1029.
40. Jongsma J, Oomen M, Noordzij M, Van Weerden WM, Martens GJM, van der Kwast TH, Schröder FH, van Steenbrugge GJ. The kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 1998; 154:543-551.
41. Krijnen J, Bogdanowitz J, Seldenrijk C, Mulder P, van der Kwast T. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171-174.
42. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate [Suppl] 1996;6:3-8.
43. Noordzij MA, van Weerden WM, van der Kwast TH, Abrahamsson PA, Gershagen S, Schröder FH, van Steenbrugge GJ. Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 1996;149:859-871.
44. Qiu Y, Robinson D, Pretlow T, Kung H-J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 1998;95:3644-3649.
45. Seethalakshmi L, Mitra S, Carraway B. Neurotensin: a growth factor of prostate cancer. Prostate [Suppl] 1996;6:96.
46. Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183-192.
47. Angelsen A, Sandvik A, Syversen U, Stridsberg M, Waldum H. NGF-β NE cells and prostatic cancer cell lines. Scand J Urol Nephrol 1998;32:7-13.
48. Geldof AA, De Kleijn MAT, Rao BR, Newling DWW. Nerve growth factor stimulates in vitro invasive capacity of DU-145 human prostatic cancer cells. J Cancer Res Clin Oncol 1997;123: 107-112.
49. Paul A, Grant E, Habib F. The expression and localisation of β-nerve growth factor (β-NGF) in benign and malignant human prostate cancer tissue: relationship to neuroendocrine differentiation. Br J Cancer 1996;74:1990-1996.
50. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Härkönen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997; 99:618-627.
51. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F. Adrenomedullin expression in human tumor cell lines. J Biol Chem 1996;271:23345-23351.
52. Bepler G, Rotsch M, Jaques G, Haeder M, Heymanns J, Hartogh G, Kiefer P, Havemann K. Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects. J Cancer Res Clin Oncol 1988;114:235-244.
53. Avis IL, Kovacs TOG, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL. Preclinical evaluation of an antiautocrine growth factor monoclonal antibody for treatment of patients with small cell lung cancer. J Natl Cancer Inst 1991; 83:1470-1476.
54. Siegfried JM, Han YH, DeMichele MAA, Hunt JD, Gaither AL, Cuttitta F. Production of gastrin-releasing peptide by a non small cell lung carcinoma cell line adapted to serum-free and growth factor free conditions. J Biol Chem 1994;269:8596-8603.
55. Pousette Å, Carlström K, Henriksson P, Grande M, Stege R. Use of a hormone-sensitive (LNCaP) and a hormone-resistant cell line in prostate cancer research. Prostate 1997;31:198-203.
56. Saeed B, Zhang H, Ng S-C. Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoalstripped media. Prostate 1997;31:145-152.
57. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
58. Dorai T, Olsson C, Katz A, Buttyan R. Development of a hammerhead ribozyme against Bcl-2.1. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate 1997;32:246-258.
59. Shen R, Dorai T, Olsson C, Katz A, Buttyan R. Steroid deprivation induces a neuronal cell phenotype in cultured prostate cancer cells. Proc AACR 1996;37:245.
60. Horoszewicz J, Leong S, Kawinsky E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-181.
61. Kaighn M, Shankar Narayan K, Ohnuki Y, Lechner J, Jones L. Establishment and characterization of a human prostatic cell line (PC3). Invest Urol 1979;17:16-23.
62. Stone K, Mickey D, Wunderli H, Mickey G, Paulson D. Isolation of a human prostate carcinoma cell line. Int J Cancer 1978;21: 274-281.
63. van Steenbrugge GJ, van Uffelen CJC, Bolt J, Schröder FH. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 1991;40:207-214.
64. Romijn J, Erkens-Schulze S, Schröder F. Perspectives of the use of tissue culture models as an alternative to human prostate cancer xenografts in nude mice. Contrib Oncol 1996;51:209-231.
65. van Weerden WM, de Ridder CMA, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schröder FH, van Steenbrugge GJ. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996;149:1055-1062.
66. Todaro G, Green H. Establishment of in vitro model for mouse fibroblasts (Swiss 3T3). J Cell Biol 1963;17:299-313.
67. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
68. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-589.
69. Hoosein N, Abdul M, Logothetis C. Significance of neuroendocrine differentiation in prostatic carcinoma. Cancer J 1996;9:291-295.
70. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996;16:287-296.
71. Reile H, Armatis P, Schally A. Characterization of high-affinity receptors for bombesin/gastrin-releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 1251-(Tyr4) bombesin by tumor cells. Prostate 1994;25:29-38.
72. Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci USA 1997;94:956-960.
73. Gonzalez C, Barroso C, Martin C, Gulbenkian S, Estrada C. Neuronal nitric oxide synthase activation by vasoactive intestinal peptide in bovine cerebral arteries. J Cereb Blood Flow Metab 1997;17:977-984.
74. Liu AY, Corey E, Bladou F, Lange PH, Vesella RL. Prostatic cell lineage markers: emergence of Bcl2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996;65:85-89.
75. Krijnen JLM, Janssen PJA, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, van der Kwast T. Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 1993;100:393-398.